Related Experiment Videos
Invasive strategy for treatment of myocardial infarction
1Ludwig-Maximilians-Universität München, Klinikum Grosshadern, Medizinische Klinik I, Munich, FRG.
Insights
Modern acute myocardial infarction (MI) treatment focuses on limiting infarct size and preserving heart function. Intravenous thrombolysis is the standard, with post-treatment strategies guided by patient symptoms and anatomy.
Area of Science:
- Cardiology
- Emergency Medicine
Background:
- Classical acute myocardial infarction (MI) treatment focused on stabilization.
- Cardiac care units and antiarrhythmic therapy have reduced MI mortality.
- Modern approaches aim to limit infarct size and preserve myocardial function.
Purpose of the Study:
- To review current treatment strategies for acute myocardial infarction.
- To compare medical and invasive treatment options.
- To discuss post-thrombolysis management.
Main Methods:
- Review of medical and invasive treatment options for acute MI.
- Discussion of intravenous (i.v.) thrombolysis, intracoronary (i.c.) thrombolysis, percutaneous transluminal coronary angioplasty (PTCA), and bypass surgery.
- Analysis of post-thrombolysis patient management strategies.
Main Results:
- Intravenous thrombolysis is the standard approach for acute MI.
- Intracoronary thrombolysis is more effective but less practical for routine use.
- Percutaneous transluminal coronary angioplasty (PTCA) and bypass surgery are effective invasive options but face logistical challenges in acute settings.
Conclusions:
- Intravenous thrombolysis is the preferred medical approach for acute MI.
- Post-thrombolysis management should be symptom-guided, with interventions like PTCA or surgery based on patient stability and coronary anatomy.
- Invasive procedures like PTCA and bypass surgery are reserved for specific cases due to logistical or anatomical considerations.
Abstract:
The classical approach to the treatment of acute myocardial infarction (MI) has been one of stabilization and complication management. In an effort to optimize treatment, the initiation of the cardiac care unit and the use of antiarrhythmic therapy have succeeded in lowering the mortality rate substantially. More modern concepts are aimed at limiting infarct size and preserving myocardial function. These aims can be achieved medically using intravenous (i.v.) thrombolysis or invasively either with intracoronary (i.c.) thrombolysis, percutaneous transluminal coronary angioplasty (PTCA), or bypass surgery. Although i.c. thrombolysis is more effective than the i.v. route, the necessity for acute coronary catheterization makes it incompatible and difficult for routine use, and thus is usually reserved for cases in which i.v. lysis has failed. Intravenous thrombolysis is becoming the standard approach to MI, and the remaining questions are those of which drug and dosage are optimal and how to approach the patient after thrombolysis. In this regard, we favor a symptom-guided approach, as shown by the TIMI-IIA and European cooperative studies. In patients with ongoing ischemia postlysis, heart catheterization is indicated and a decision regarding PTCA or surgery is then made, depending on anatomy. In patients remaining stable after acute lysis, a predischarge stress may help in selecting patients requiring catheterization. As an alternative invasive approach to acute MI, PTCA may be the quickest and most effective method to recanalize a vessel, but, again, logistical problems make it incompatible in the acute setting. The same is true for bypass surgery, and although extensive improvements have been made in intraoperative myocardial preservation so that a 2% mortality is achievable, it is reserved for patients with extensive ischemia and anatomy unsuitable for PTCA (extensive multivessel or left main disease).